Prostate cancer stands as one of the most studied malignancies worldwide, yet despite its prevalence and high curability especially in localized stages, a profoundly aggressive subset remains enigmatic and deadly. Recent advances spearheaded by a collaborative team led by CIC bioGUNE, in concert with several Spanish clinical and research institutions, have unearthed critical molecular insights into metastatic hormone-naïve prostate cancer (mHNPC). This research delves deep into the tumor biology of primary biopsies from patients manifesting metastasis at diagnosis—a group representing a small portion of all prostate cancers but accounting disproportionately for mortality. Through an unprecedented transcriptional analysis, this study uncovers a distinct biological fingerprint defining this lethal form, highlighting novel mechanisms of tumor aggressiveness that could reshape diagnostic and treatment paradigms.
Cancer, broadly viewed as a heterogeneous collection of diseases, demands precision oncology approaches that dissect its molecular complexity at refined scales. Prostate cancer exemplifies this diversity, with approximately 90% of patients diagnosed bearing tumors amenable to successful treatment. However, metastatic prostate cancer present at diagnosis, although constituting merely 5-10% of cases, poses a significant challenge due to its aggressive clinical behavior and the substantial mortality burden it carries. The multifaceted nature of this variant has historically complicated efforts to fully understand and effectively target it. Recognizing the urgent need for molecular subtyping and tailored therapies, the interdisciplinary team embarked on a comprehensive project beginning in 2018, leveraging advanced molecular technologies and analytical frameworks.
Central to the endeavor was accessing a decade’s worth of archived tissue samples from Basurto University Hospital. This extensive repository provided a robust sample size essential for detecting subtle transcriptional signatures indicative of aggressive disease phenotypes. Strikingly, logistical innovations were implemented to ensure swift processing—enable tissue to be transferred to research labs within hours to preserve RNA integrity critical for subsequent high-resolution transcriptomic profiling. The integration of clinical expertise, molecular biology, and computational prowess created a seamless workflow to interrogate the complexity of metastatic prostate cancer at an unprecedented depth.
.adsslot_cpQPkR0b4D{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_cpQPkR0b4D{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_cpQPkR0b4D{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
One of the pivotal breakthroughs came from applying computational decomposition methods that treat tumors not as a homogenous mass but as intricate ecosystems composed of heterogeneous cellular entities. Traditional bulk analyses often obscure this cellular mosaic, rendering impossible the disentangling of cancer cells from the stromal, immune, and other microenvironmental components. By effectively “untangling the tumor smoothie” into individual fruit slices, researchers gained an unparalleled resolution to map gene expression patterns unique to the cancer cells driving metastasis and their interaction with surrounding normal cells.
The analysis elucidated that metastatic prostate cancer cells adopt a distinctive communication language, orchestrating behaviors in adjacent normal cells that facilitate tumor progression. This novel form of intercellular crosstalk reveals previously uncharacterized pathways through which cancer cells “educate” their environment, modulating immune responses, extracellular matrix remodeling, and angiogenesis to ensure survival and dissemination. The findings challenge existing dogma and underscore the complexity of tumor-host interactions, which might serve as vulnerabilities exploitable by future therapeutic interventions.
Among several molecular players identified, SOX11—a transcription factor not previously highlighted in prostate cancer dissemination—emerged as a key regulator. Its elevated expression correlates with the propensity of cancer cells to metastasize, pointing to a functional role in enabling cellular plasticity and motility. The identification of SOX11’s involvement opens new avenues for biomarker development and targeted treatment strategies aimed at intercepting metastatic spread at its nascent stages.
The study’s success hinged on a concerted effort spanning multiple institutions across Spain, including leading hospitals and renowned research centers such as IRB Barcelona, VHIO, and the Josep Carreras Institute. This extensive network amplified the study’s scale and impact, providing heterogeneous patient samples and methodological expertise. Such collaborations exemplify the power of integrative research frameworks and highlight the critical role of national biomedical networks like the Spanish Biomedical Research Network in Oncology (CIBERONC), which fosters synergy between basic and translational scientists.
Precision oncology’s future rests on the ability to decode tumors’ molecular intricacies and translate findings into clinical practice swiftly. Insights from this study not only deepen understanding of metastatic hormone-naïve prostate cancer’s biology but also lay a foundation for refining clinical guidelines, improving early diagnosis, and personalizing therapeutic approaches. Early identification of patients likely to develop aggressive disease forms will facilitate precision interventions, potentially altering the unfavorable prognoses currently observed in this subgroup.
The implications of these findings extend beyond prostate cancer, spotlighting the concept that biological heterogeneity within cancers must be acknowledged and dissected to achieve meaningful clinical breakthroughs. The novel methods and analytical tools deployed set a precedent for approaching other cancers exhibiting variable metastatic patterns, reinforcing the necessity of dissecting tumor microenvironments at granular levels.
CIC bioGUNE’s leadership and innovation in this research exemplify how cutting-edge bioscience facilities, supported by alliances such as BRTA and funding from the Asociación Española Contra el Cáncer (AECC), accelerate advances in cancer biology. This cohesive ecosystem of scientific excellence, technical infrastructure, and clinical integration fosters discoveries that translate from bench to bedside.
The challenges addressed herein—rapid tissue procurement, high-throughput molecular profiling, computational deconvolution, and collaborative cross-institutional studies—embody the complex orchestration required to tackle aggressive cancers effectively. As molecular diagnostics evolve, the importance of such multidisciplinary efforts, robust biobanks, and computational innovation becomes increasingly critical.
In summary, this landmark transcriptional study not only pinpoints a distinct biological entity within metastatic hormone-naïve prostate cancer but sets the stage for novel diagnostic and therapeutic directions. By unveiling the molecular “language” employed by cancer cells, and identifying pivotal regulators like SOX11, researchers forge pathways toward mitigating a highly lethal cancer subset. Continued efforts informed by this foundational research promise to enhance patient stratification and intervention, advancing global objectives in precision oncology and improving survival outcomes.
Subject of Research: Cells
Article Title: Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination
News Publication Date: 3-Jun-2025
Web References:
https://genomebiology.biomedcentral.com/articles/10.1186/s13059-025-03623-5
References:
Natalia Martin-Martin, Saioa Garcia-Longarte, Jon Corres-Mendizabal, Uxue Lazcano, Ianire Astobiza, Laura Bozal-Basterra, Nicolas Herranz, Hielke van Splunder, Onintza Carlevaris, Mikel Pujana-Vaquerizo, María Teresa Blasco, Ana M. Aransay, Antonio Rosino, Julian Tudela, Daniel Jimenez, Alberto Martinez, Andrei Salca, Aida Santos-Martín, Sofía Rey, Aitziber Ugalde-Olano, David Gonzalo, Mariona Graupera, Roger R. Gomis, Joaquin Mateo, Miguel Unda, Enrique Gonzalez-Billalabeitia, Ana Loizaga-Iriarte, Isabel Mendizabal & Arkaitz Carracedo. “Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination.” Genome Biol. DOI: 10.1186/s13059-025-03623-5
Keywords: Prostate cancer, Metastatic prostate cancer, Hormone-naïve, SOX11, Tumor microenvironment, Transcriptomics, Precision oncology, Cancer heterogeneity, Molecular diagnostics, Tumor dissemination, Cancer cell communication, Computational deconvolution
Tags: aggressive prostate cancer subtypesbiological fingerprint of aggressive tumorsCIC bioGUNE prostate cancer researchcollaborative cancer research in Spaindiagnostic challenges in prostate cancermetastatic hormone-naïve prostate cancermolecular insights into prostate cancerprecision oncology approachesprostate cancer mortality ratestranscriptional analysis in cancertreatment paradigms for metastatic cancertumor biology of prostate cancer
